SCHEMBL22490727

SCHEMBL22490727

COC(=O)c1nc(NS(=O)(=O)C2CC2)sc1Cl

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CTPS1 P17812 11/20 0.38
NPSR1 Q6W5P4 1/20 0.36
SMN1; SMN2 Q16637 3/20 0.33
KDM4E B2RXH2 2/20 0.33
PKM P14618 2/20 0.33
CTPS2 Q9NRF8 2/20 0.33
ALDH1A1 P00352 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
PIK3CA P42336 1/20 0.32
JAK1 P23458 1/20 0.32
MAPT P10636 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
RCE1 Q9Y256 1/20 0.32
TPH1 P17752 1/20 0.31
NPC1 O15118 1/20 0.30
HSP90AA1 P07900 1/20 0.30
RAB9A P51151 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22869102 0.77 CTPS1 (0.37) CTPS1CTPS2
SCHEMBL22490846 0.74 CTPS1 (0.37) CTPS1CTPS2
SCHEMBL22490826 0.74 GAA (0.55) CTPS1NPSR1SMN1; SMN2KDM4ECTPS2
SCHEMBL22869128 0.74 CTPS1 (0.38) CTPS1CTPS2
SCHEMBL9861429 0.73 NPSR1 (0.45) NPSR1SMN1; SMN2KDM4EPKMALDH1A1
SCHEMBL22490823 0.72 CTPS1 (0.35) CTPS1SMN1; SMN2CTPS2L3MBTL1
SCHEMBL22490868 0.69 CTPS1 (0.39) CTPS1CTPS2ALDH1A1
SCHEMBL9860580 0.69 NPSR1 (0.52) NPSR1SMN1; SMN2KDM4EPKMALDH1A1
SCHEMBL20495112 0.69 NPSR1 (0.40) NPSR1SMN1; SMN2KDM4EPKMALDH1A1
SCHEMBL12228844 0.68 NPSR1 (0.50) NPSR1SMN1; SMN2KDM4EPKMALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3717465-B1 COMPOUNDS STEP PHARMA S A S (FR) 2026-01-21 EP disclosed
US-20250263407-A1 Compounds STEP PHARMA S.A.S. (FR) 2025-08-21 US disclosed
US-12319680-B2 Compounds STEP PHARMA S.A.S. (FR) 2025-06-03 US disclosed
US-20230183229-A1 Compounds SYGNATURE DISCOVERY LIMITED (GB) 2023-06-15 US disclosed
US-20230183229-A1 Compounds SYGNATURE DISCOVERY LIMITED (GB) 2023-06-15 US disclosed
US-20230183229-A1 Compounds SYGNATURE DISCOVERY LIMITED (GB) 2023-06-15 US disclosed
US-11505547-B2 Compounds STEP PHARMA S.A.S. (FR) 2022-11-22 US disclosed
US-20210380575-A1 COMPOUNDS SYGNATURE DISCOVERY LIMITED (GB) 2021-12-09 US disclosed
US-20210380575-A1 COMPOUNDS SYGNATURE DISCOVERY LIMITED (GB) 2021-12-09 US disclosed
EP-3717465-A1 COMPOUNDS Step Pharma S.A.S. (FR) 2020-10-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230183229-A1 Compounds UGT1A1, CYP1A1, CYP1B1 CTPS1 2556/4885NPSR1 1179/4885SMN1; SMN2 2367/4885
US-12319680-B2 Compounds UGT1A1, CYP1A1, CYP1B1 CTPS1 2556/4885NPSR1 1179/4885SMN1; SMN2 2367/4885
US-20250263407-A1 Compounds CYP1A1, UGT1A1, CYP1A2 CTPS1 2586/4885NPSR1 1007/4885SMN1; SMN2 1991/4885
US-11505547-B2 Compounds UGT1A1, CYP1A1, CYP1B1 CTPS1 2556/4885NPSR1 1179/4885SMN1; SMN2 2367/4885
US-20210380575-A1 COMPOUNDS UGT1A1, CYP1A1, CYP1B1 CTPS1 2556/4885NPSR1 1179/4885SMN1; SMN2 2367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.